Ten post jest także dostępny w języku: polski
On 15 December 2020, Biomd-Lubin signed an agreement with the Minister of Finance, Funds and Regional Policy for co-financing the Project: “BCG biotechnological innovation centre”. As part of these funds, the company received nearly PLN 29.2m for the creation of the centre, in order to develop technologies related to vaccinology in the prevention of tuberculosis and immunology in cancer therapy, the company reported.
60% of eligible costs from the OP Intelligent Development
Biomed-Lublin informed that the total investment cost is over PLN 48.6m. The subsidy thus constitutes 60% of eligible costs. The funding obtained comes from the Operational Programme (OP) Intelligent Development 2014-2020, under the second priority axis: “Support for environment and potential of enterprises to conduct R&D&I activities”. The company’s current report published on the PAP website states that according to the co-financing agreement, the investment must be completed by 31 August 2022.
On the Biomed-Lublin website, dated 16 December 2020, there has already been an enquiry for the execution of construction works for the construction of a research and development building within the Centre for Biotechnological Innovations. The enquiry indicated that the Onko BCG Plant at Glowna Street will be built.